Cabozantinib Prostate Cancer Bone Scans – Part 2 of an interview with Dr Maha Hussain
This is part 2 of my interview with Dr Maha Hussain, Professor of Medical Oncology at the University of Michigan. You can read part 1 about cabozantinib and pain here.
At the 2011 ASCO annual meeting, Dr Hussain presented data from a non-randomized phase 2 trial with cabozantinib that showed dramatic improvements in bone scans before and after treatment.
Bones are living tissues that are constantly being remade, a dynamic process that involves formation of new bone and taking up of old bone, a process known as bone resorption. Cancer cells can interfere with bone remodeling, resulting in increased new bone formation (osteoblastic response) or excessive bone resorption (osteoclastic response).
The market for prostate cancer therapies is set to expand from $1 billion currently to $5 billion by 2015, according to analysts reported by